Adocia Welcomes Internationally Renowned Diabetes Experts to Inaugural Medical Advisory Board

Regulatory News:

ADOCIA (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on developing innovative formulations of existing therapeutic proteins, today announced the formation of its new Global Diabetes Medical Advisory Board (MAB) consisting of well-respected endocrinologists from the US and EU.

The MAB will serve as an ongoing key strategic resource to ADOCIA for the development of its expanding diabetes portfolio. In the near term, MAB engagement will focus on the development of BioChaperone Combo, a unique combination of the basal insulin glargine and the prandial insulin lispro, currently in phase 2.

"We are extremely proud and honored to welcome these world-leading experts in diabetes to our Medical Advisory Board,” said Olivier Soula, Deputy General Manager and R&D Director of ADOCIA. "The specific background and extensive experience of each member brings invaluable insight to ADOCIA. We are particularly looking forward to further demonstrating the value of BioChaperone Combo and optimizing the next clinical studies to advance this key program into later clinical stage development.”

The inaugural nine-member board will be chaired by Dr. Jay Skyler, Professor of Medicine, Pediatrics & Psychology at the University of Miami, Miami, Florida (USA).

"I am delighted to take the role of Chairman to ADOCIA’s Diabetes Medical Advisory Board and be part of the development of their exciting innovative products”, said Dr Jay Skyler, Professor at the University of Miami. "I am especially pleased by the depth of experience and leadership in the diabetes field represented at the board, and I look forward to contributing to the development of BioChaperone Combo, a potentially promising treatment option for many diabetic patients requiring intensive insulin therapy.”

The inaugural members of ADOCIA’s Medical Advisory Board include:

Dr Jay Skyler, MD, Chairman of ADOCIA’s Diabetes Medical Advisory Board. Dr Skyler is a Professor of Medicine, Pediatrics & Psychology at the University of Miami (USA), in the Division of Endocrinology, Diabetes & Metabolism in the Department of Medicine, of which he was the Director from 2000 to 2004; and Associate Director for Academic Programs in the Diabetes Research Institute.

Dr Vanita Aroda, MD, is a Physician Investigator at MedStar Health Research Institute (MHRI), Hyattsville (USA). Dr. Aroda also serves as Scientific Director of the MedStar Community Clinical Research Center.

Dr. Bruce Bode, MD, is a Clinical Associate Professor in the Department of Medicine at Emory University, Atlanta (USA) and a diabetes specialist with Atlanta Diabetes Associates.

Dr John Buse, MD, PhD, is a professor at the University of North Carolina, School of Medicine in Chapel Hill (USA) where he serves as the Director of the Diabetes Care Center, Chief of the Division of Endocrinology and Executive Associate Dean for Clinical Research.

Dr. William Cefalu, MD, is the executive director of Louisiana State University’s Pennington Biomedical Research Center (USA). He also holds the George A. Bray Endowed Super Chair in Nutrition.

Dr. Dan Einhorn, MD, is the President of Diabetes and Endocrine Associates as well as Clinical Professor of Medicine at the University of California, San Diego (USA). He also serves as Medical Director of the Scripps Whittier Diabetes Institute.

Dr. Vivian Fonseca, MD, is Professor of Medicine, Tullis–Tulane Alumni Chair in Diabetes, Section of Endocrinology at Tulane University Health Sciences Center (USA).

Dr. Chantal Mathieu MD, PhD, is currently Director of the Endocrinology Clinic at the University Hospital of Leuven (Belgium). She also serves as Professor of Endocrinology at the University of Leuven.

Prof. Denis Raccah, MD, PhD, is currently Professor at the Assistance Publique des Hôpitaux de Marseille (APHM) and Director of the Department of Nutrition, Metabolic Diseases and Endocrinology at the Sainte Marguerite Hospital and the Conception Hospital (Marseille, France).

About ADOCIA

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s insulin formulations portfolio, featuring four clinical-stage programs and one preclinical program, is among the largest and most differentiated in the industry.

The proprietary BioChaperone^® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.

Adocia’s clinical pipeline includes a unique formulation of PDGF-BB for the treatment of diabetic foot ulcer and four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin lispro (BioChaperone Lispro U100 and U200), a combination of slow-acting insulin glargine and rapid-acting insulin lispro (BioChaperone Combo) and a rapid-acting formulation of human insulin (HinsBet U100). Adocia is also developing a concentrated, rapid-acting formulation of human insulin (HinsBet U500).
In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro programs.

Adocia’s extended, early-stage programs include innovative monoclonal antibody formulations, featuring two ongoing collaborations programs with major pharmaceutical companies in the field, and the delivery of anticancer drugs using the proprietary DriveIn^® nanotechnology platform.

Adocia aims to deliver "Innovative medicine for everyone, everywhere.”

To learn more about Adocia, please visit us at www.adocia.com

Disclaimer
This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the ‘Risk Factors’ section of the Reference Document registered by the French Autorité des marchés financiers on April 30, 2015 under number R.15-032 (a copy of which is available on www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements.
This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160321005972/en/